Prediction of prognosis and immune checkpoint inhibitor response to anti-PD-1 therapy in patients with metastatic melanoma based on apoptotic cell clearance-related signatures
Letters in Drug Design & Discovery · 2026-10 · 100648
DOI: 10.1016/j.lddd.2026.100648 ↗Kurz gefasst
Fachartikel in der Zeitschrift Letters in Drug Design & Discovery, 2026-10. Verfasst von Yongchang Guo und 2 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Guo, Y., Wang, Y., & Li, H. (2026). Prediction of prognosis and immune checkpoint inhibitor response to anti-PD-1 therapy in patients with metastatic melanoma based on apoptotic cell clearance-related signatures. Letters in Drug Design & Discovery, 100648. https://doi.org/10.1016/j.lddd.2026.100648
Vancouver
Guo Y, Wang Y, Li H. Prediction of prognosis and immune checkpoint inhibitor response to anti-PD-1 therapy in patients with metastatic melanoma based on apoptotic cell clearance-related signatures. Letters in Drug Design & Discovery. 2026:100648. doi:10.1016/j.lddd.2026.100648
BibTeX
@article{Guo2026,
author = {Guo, Yongchang and Wang, Yali and Li, Hui},
title = {Prediction of prognosis and immune checkpoint inhibitor response to anti-PD-1 therapy in patients with metastatic melanoma based on apoptotic cell clearance-related signatures},
journal = {Letters in Drug Design & Discovery},
year = {2026},
pages = {100648},
doi = {10.1016/j.lddd.2026.100648}
}
EUVIMED